NewLink Genetics Corp (NASDAQ:NLNK) saw a large growth in short interest in October. As of October 31st, there was short interest totalling 1,790,000 shares, a growth of 44.4% from the September 30th total of 1,240,000 shares. Currently, 6.2% of the shares of the company are sold short. Based on an average daily trading volume, of 304,000 shares, the days-to-cover ratio is presently 5.9 days.
A number of analysts recently commented on NLNK shares. ValuEngine upgraded shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research cut shares of NewLink Genetics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd.
NASDAQ NLNK traded down $0.01 on Monday, hitting $1.53. The stock had a trading volume of 111,653 shares, compared to its average volume of 395,513. NewLink Genetics has a 52-week low of $1.13 and a 52-week high of $2.27. The company has a debt-to-equity ratio of 0.08, a quick ratio of 12.77 and a current ratio of 12.77. The company has a market capitalization of $58.58 million, a price-to-earnings ratio of -1.06 and a beta of 1.03. The firm has a 50-day moving average of $1.45 and a 200-day moving average of $1.59.
A number of hedge funds and other institutional investors have recently bought and sold shares of NLNK. Vanguard Group Inc. lifted its stake in NewLink Genetics by 30.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,412,900 shares of the biotechnology company’s stock worth $2,091,000 after purchasing an additional 330,510 shares in the last quarter. Renaissance Technologies LLC lifted its stake in NewLink Genetics by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,927,465 shares of the biotechnology company’s stock worth $4,333,000 after purchasing an additional 205,652 shares in the last quarter. Acadian Asset Management LLC lifted its stake in NewLink Genetics by 35.2% in the 2nd quarter. Acadian Asset Management LLC now owns 546,290 shares of the biotechnology company’s stock worth $808,000 after purchasing an additional 142,207 shares in the last quarter. Paloma Partners Management Co purchased a new stake in NewLink Genetics in the 2nd quarter worth approximately $191,000. Finally, Requisite Capital Management LLC purchased a new stake in NewLink Genetics in the 2nd quarter worth approximately $185,000. Institutional investors and hedge funds own 29.96% of the company’s stock.
NewLink Genetics Company Profile
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.
Read More: 12b-1 Fees
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.